{"id":351413,"date":"2026-11-18T09:43:58","date_gmt":"2026-11-18T04:13:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=351413"},"modified":"2026-11-18T09:43:58","modified_gmt":"2026-11-18T04:13:58","slug":"amrutanjan-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/","title":{"rendered":"Amrutanjan Analyst Review 2027: Q2 Profit Up 24%, Hygiene Grows Fast and the Stock Sits Near Its Low"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Amrutanjan Health Care Stock Snapshot (17 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b9508.30<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b9725.60 \/ \u20b9476.50<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b91,471 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 25.7 vs 51.5<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b9135.18 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b917.28 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Amrutanjan analyst review 2027<\/strong> shows a strong second quarter after a weak first. Q2 FY27 net sales rose about 14.9% to \u20b9135.18 crore and profit rose about 23.8% to \u20b917.28 crore, but H1 profit was \u20b921.65 crore, slightly below last year. No named brokerage covers the stock, so there is no published <strong>Amrutanjan share price target 2027<\/strong>. At \u20b9508.30, the stock is about 30% below its 52-week high and close to its low, at a P\/E near 25.7, about half its industry level.<\/p>\n<\/div>\n<p>The <strong>Amrutanjan analyst review 2027<\/strong> covers the Chennai-based maker of the Amrutanjan pain balm, the Comfy women&#8217;s hygiene range and Electro+ rehydration drinks. Anyone searching for an <strong>Amrutanjan share price target 2027<\/strong> will not find a dated target from a named research firm, so this review works from results and management guidance.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/amrutanjan\/amrutanjan-health-care-ltd-share-price-today\">Amrutanjan Health Care<\/a> closed at \u20b9508.30 on 17 November 2026, about 30% below its 52-week high of \u20b9725.60 and about 7% above its low of \u20b9476.50. This Amrutanjan analyst review 2027 covers the latest quarter, the brand portfolio and the <strong>Amrutanjan stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=amrutanjan-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#What_Analysts_Say_in_the_Amrutanjan_Analyst_Review_2027\" title=\"What Analysts Say in the Amrutanjan Analyst Review 2027\">What Analysts Say in the Amrutanjan Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Q2_FY27_Results_in_the_Amrutanjan_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Amrutanjan Analyst Review 2027\">Q2 FY27 Results in the Amrutanjan Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#How_Amrutanjan_Makes_Money\" title=\"How Amrutanjan Makes Money\">How Amrutanjan Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Growth_Triggers_in_the_Amrutanjan_Analyst_Review_2027\" title=\"Growth Triggers in the Amrutanjan Analyst Review 2027\">Growth Triggers in the Amrutanjan Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Key_Risks_in_the_Amrutanjan_Analyst_Review_2027\" title=\"Key Risks in the Amrutanjan Analyst Review 2027\">Key Risks in the Amrutanjan Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Amrutanjan_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Amrutanjan Analyst Review 2027: Stock at a Glance\">Amrutanjan Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#What_to_Watch_After_the_Amrutanjan_Analyst_Review_2027\" title=\"What to Watch After the Amrutanjan Analyst Review 2027\">What to Watch After the Amrutanjan Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Final_Word_on_the_Amrutanjan_Analyst_Review_2027\" title=\"Final Word on the Amrutanjan Analyst Review 2027\">Final Word on the Amrutanjan Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#What_does_the_Amrutanjan_analyst_review_2027_show\" title=\"What does the Amrutanjan analyst review 2027 show?\">What does the Amrutanjan analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Is_there_an_Amrutanjan_share_price_target_2027_from_brokerages\" title=\"Is there an Amrutanjan share price target 2027 from brokerages?\">Is there an Amrutanjan share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Which_Amrutanjan_segments_are_growing_fastest\" title=\"Which Amrutanjan segments are growing fastest?\">Which Amrutanjan segments are growing fastest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Why_was_Amrutanjans_H1_profit_lower_despite_higher_sales\" title=\"Why was Amrutanjan&#8217;s H1 profit lower despite higher sales?\">Why was Amrutanjan&#8217;s H1 profit lower despite higher sales?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#Is_Amrutanjan_expensive_based_on_the_Amrutanjan_analyst_review_2027\" title=\"Is Amrutanjan expensive, based on the Amrutanjan analyst review 2027?\">Is Amrutanjan expensive, based on the Amrutanjan analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#What_risks_does_the_Amrutanjan_analyst_review_2027_highlight\" title=\"What risks does the Amrutanjan analyst review 2027 highlight?\">What risks does the Amrutanjan analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/amrutanjan-analyst-review\/#What_should_investors_track_after_the_Amrutanjan_analyst_review_2027\" title=\"What should investors track after the Amrutanjan analyst review 2027?\">What should investors track after the Amrutanjan analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Analysts_Say_in_the_Amrutanjan_Analyst_Review_2027\"><\/span><strong>What Analysts Say in the Amrutanjan Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>No verified coverage<\/td>\n<td>Not available<\/td>\n<td>Not available<\/td>\n<td>As of November 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>No dated <strong>brokerage<\/strong> report with a rating and target on Amrutanjan could be traced. Domestic institutions cut their stake to 6.90% from 12.90% during the year, and foreign investors hold about 3.5%, so research interest is limited.<\/p>\n<p>That shapes the Amrutanjan analyst review 2027. Management guidance carries more weight than usual. The company has guided to 12% to 15% revenue growth in FY27 and a goal of sustaining about a 12% operating margin. Any target shared without a named, registered source should be treated with caution.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Amrutanjan_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Amrutanjan Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Net Sales<\/td>\n<td>\u20b9135.18 crore<\/td>\n<td>\u20b9117.70 crore<\/td>\n<td>+14.85%<\/td>\n<\/tr>\n<tr>\n<td>Profit Before Tax<\/td>\n<td>\u20b923.10 crore<\/td>\n<td>\u20b919.21 crore<\/td>\n<td>+20.25%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit<\/td>\n<td>\u20b917.28 crore<\/td>\n<td>\u20b913.96 crore<\/td>\n<td>+23.78%<\/td>\n<\/tr>\n<tr>\n<td>H1 Net Sales<\/td>\n<td>\u20b9238.15 crore<\/td>\n<td>\u20b9211.75 crore<\/td>\n<td>+12.47%<\/td>\n<\/tr>\n<tr>\n<td>H1 Net Profit<\/td>\n<td>\u20b921.65 crore<\/td>\n<td>\u20b922.27 crore<\/td>\n<td>-2.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Q2 FY27<\/strong> net sales rose about 14.9% to \u20b9135.18 crore, profit before tax rose about 20% to \u20b923.10 crore and net profit rose about 23.8% to \u20b917.28 crore. Management said operating margin expanded by about 200 basis points despite cost inflation, helped by better fixed cost absorption.<\/p>\n<p>The first half was weaker. Q1 FY27 profit fell to about \u20b94.4 crore from \u20b98.3 crore, partly because of lower operating profit and exceptional items. As a result, H1 profit of \u20b921.65 crore was slightly below the year before even though H1 sales rose about 12.5%. For the Amrutanjan analyst review 2027, Q2 is a recovery quarter rather than proof of a new trend.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Amrutanjan_Makes_Money\"><\/span><strong>How Amrutanjan Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Pain management:<\/strong> balms, roll-ons and sprays under the Amrutanjan brand, the company&#8217;s original business. Sales rose about 6.1% in H1 FY27.<\/li>\n<li><strong>Women&#8217;s hygiene:<\/strong> sanitary napkins under the Comfy brand, the fastest-growing category at about 20.5% in H1.<\/li>\n<li><strong>Rehydration beverages:<\/strong> Electro+ drinks, which grew about 1% in H1 but fell about 21.4% in Q2.<\/li>\n<li><strong>Distribution:<\/strong> sales through chemists, general trade, modern trade and online.<\/li>\n<\/ul>\n<p>The business carries no debt, with <strong>debt to equity<\/strong> at 0.00, and earns a return on equity of about 17%. Category mix is the main driver of margins, which is why the Amrutanjan analyst review 2027 tracks each segment separately.<\/p>\n<p>The mix is shifting. The balm business is mature and grows slowly, but it earns strong margins and funds the newer categories. Women&#8217;s hygiene is growing quickly from a smaller base and needs marketing spend to build share against larger rivals. Beverages are seasonal and swing more from quarter to quarter. The net effect is that overall growth now depends more on Comfy and on distribution reach, while profit still leans on the balm franchise.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Amrutanjan_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Amrutanjan Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Women&#8217;s hygiene growth:<\/strong> Comfy grew about 20.5% in H1 FY27.<\/li>\n<li><strong>Chemist expansion:<\/strong> the company plans to build 1,00,000 direct chemist outlets in FY27.<\/li>\n<li><strong>Margin gains:<\/strong> operating margin expanded about 200 basis points in Q2.<\/li>\n<li><strong>Revenue guidance:<\/strong> 12% to 15% growth targeted for FY27, with H1 at about 12.5%.<\/li>\n<li><strong>Debt-free balance sheet:<\/strong> no borrowings and steady dividends, a base in the Amrutanjan analyst review 2027.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Amrutanjan_Analyst_Review_2027\"><\/span><strong>Key Risks in the Amrutanjan Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Weak first half:<\/strong> H1 FY27 profit was slightly below last year.<\/li>\n<li><strong>Beverage slowdown:<\/strong> rehydration sales fell about 21.4% in Q2.<\/li>\n<li><strong>Slow core growth:<\/strong> pain management grew only about 6% in H1.<\/li>\n<li><strong>Cost inflation:<\/strong> rising input costs can squeeze margins.<\/li>\n<li><strong>Domestic selling:<\/strong> domestic institutions halved their stake to 6.90% from 12.90%.<\/li>\n<li><strong>No research coverage:<\/strong> no named targets to anchor expectations.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Amrutanjan Health Care With FMCG and OTC Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Amrutanjan_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Amrutanjan Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (17 Nov 2026 close)<\/td>\n<td>\u20b9508.30<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b9725.60 \/ \u20b9476.50<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b91,471 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM) vs Industry<\/td>\n<td>25.7 vs 51.5<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>3.83<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>\u20b9132.80<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>17.07%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.96%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>\u20b919.82<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>A <strong>P\/E<\/strong> near 25.7 is about half the industry figure of about 51.5, while price to <strong>book value<\/strong> is about 3.8. For a debt-free consumer health company with a 17% return on equity, the Amrutanjan analyst review 2027 points to a valuation that reflects slow growth in the core balm business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>46.52%<\/td>\n<td>46.52%<\/td>\n<td>No change<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>2.38%<\/td>\n<td>3.47%<\/td>\n<td>+1.09 pts<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>12.90%<\/td>\n<td>6.90%<\/td>\n<td>-6.00 pts<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>38.20%<\/td>\n<td>43.11%<\/td>\n<td>+4.91 pts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>promoter<\/strong> group, led by Goodhealth Holdings at 20.15% and Sambhuprasad Sivalenka at 10.34%, holds a steady 46.52%. Domestic institutions sold six percentage points, which helps explain the price fall. That selling is the biggest ownership shift in the Amrutanjan analyst review 2027 period.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Amrutanjan_Analyst_Review_2027\"><\/span><strong>What to Watch After the Amrutanjan Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>H2 growth:<\/strong> whether sales growth reaches the 12% to 15% guided range for the full year.<\/li>\n<li><strong>Margins:<\/strong> progress towards the 12% operating margin goal.<\/li>\n<li><strong>Comfy momentum:<\/strong> whether women&#8217;s hygiene keeps growing near 20%.<\/li>\n<li><strong>Beverage recovery:<\/strong> Electro+ sales after a 21% fall in Q2.<\/li>\n<li><strong>Research coverage:<\/strong> a named note would provide an Amrutanjan share price target 2027 reference.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Amrutanjan_Analyst_Review_2027\"><\/span><strong>Final Word on the Amrutanjan Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Amrutanjan analyst review 2027<\/strong> shows a debt-free consumer health company that bounced back in <strong>Q2 FY27<\/strong>, with sales up about 15% and profit up about 24%. A weak Q1 left H1 profit slightly lower, and domestic funds have sold.<\/p>\n<p>The <strong>Amrutanjan stock outlook 2027<\/strong> depends on hygiene growth, a recovery in beverages and margins moving towards 12%. The stock trades at about half its industry <strong>P\/E<\/strong>. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Amrutanjan_analyst_review_2027_show\"><\/span><strong>What does the Amrutanjan analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows a strong Q2 after a weak Q1, with no named research coverage. Q2 FY27 net sales rose about 14.9% to \u20b9135.18 crore and profit rose about 23.8% to \u20b917.28 crore. H1 profit of \u20b921.65 crore was slightly below last year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_there_an_Amrutanjan_share_price_target_2027_from_brokerages\"><\/span><strong>Is there an Amrutanjan share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>No dated brokerage target could be verified as of November 2026. Management has guided to 12% to 15% revenue growth for FY27. The stock closed at \u20b9508.30 on 17 November 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_Amrutanjan_segments_are_growing_fastest\"><\/span><strong>Which Amrutanjan segments are growing fastest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Women&#8217;s hygiene under the Comfy brand grew about 20.5% in H1 FY27. Pain management grew about 6.1%. Rehydration drinks grew about 1% in H1 but fell about 21.4% in Q2.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_was_Amrutanjans_H1_profit_lower_despite_higher_sales\"><\/span><strong>Why was Amrutanjan&#8217;s H1 profit lower despite higher sales?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Q1 FY27 profit fell to about \u20b94.4 crore from \u20b98.3 crore because of lower operating profit and exceptional items. Q2 profit recovered to \u20b917.28 crore. H1 sales still rose about 12.5% to \u20b9238.15 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Amrutanjan_expensive_based_on_the_Amrutanjan_analyst_review_2027\"><\/span><strong>Is Amrutanjan expensive, based on the Amrutanjan analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The P\/E of about 25.7 is about half the industry figure of about 51.5. Price to book is about 3.8 and return on equity is about 17%. The company has no debt.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Amrutanjan_analyst_review_2027_highlight\"><\/span><strong>What risks does the Amrutanjan analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are a weak first half, a fall in beverage sales and slow growth in pain balms. Domestic institutions cut their stake to 6.90% from 12.90%. Input cost inflation can also hurt margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Amrutanjan_analyst_review_2027\"><\/span><strong>What should investors track after the Amrutanjan analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track full-year sales against the 12% to 15% guidance and margins against the 12% goal. Watch Comfy growth and any recovery in Electro+. A first named brokerage note would add a reference point.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Amrutanjan analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows a strong Q2 after a weak Q1, with no named research coverage. Q2 FY27 net sales rose about 14.9% to \u20b9135.18 crore and profit rose about 23.8% to \u20b917.28 crore. H1 profit of \u20b921.65 crore was slightly below last year.\"}},{\"@type\":\"Question\",\"name\":\"Is there an Amrutanjan share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No dated brokerage target could be verified as of November 2026. Management has guided to 12% to 15% revenue growth for FY27. The stock closed at \u20b9508.30 on 17 November 2026.\"}},{\"@type\":\"Question\",\"name\":\"Which Amrutanjan segments are growing fastest?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Women's hygiene under the Comfy brand grew about 20.5% in H1 FY27. Pain management grew about 6.1%. Rehydration drinks grew about 1% in H1 but fell about 21.4% in Q2.\"}},{\"@type\":\"Question\",\"name\":\"Why was Amrutanjan's H1 profit lower despite higher sales?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Q1 FY27 profit fell to about \u20b94.4 crore from \u20b98.3 crore because of lower operating profit and exceptional items. Q2 profit recovered to \u20b917.28 crore. H1 sales still rose about 12.5% to \u20b9238.15 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Amrutanjan expensive, based on the Amrutanjan analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E of about 25.7 is about half the industry figure of about 51.5. Price to book is about 3.8 and return on equity is about 17%. The company has no debt.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Amrutanjan analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are a weak first half, a fall in beverage sales and slow growth in pain balms. Domestic institutions cut their stake to 6.90% from 12.90%. Input cost inflation can also hurt margins.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Amrutanjan analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track full-year sales against the 12% to 15% guidance and margins against the 12% goal. Watch Comfy growth and any recovery in Electro+. A first named brokerage note would add a reference point.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Amrutanjan Health Care grew Q2 FY27 sales about 15% and profit about 24% to \u20b917.28 crore, but H1 profit was slightly lower after a weak Q1. No named brokerage target exists. We review results, segments, guidance, valuation and risks for 2027.<\/p>\n","protected":false},"author":38,"featured_media":351412,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,25430,4341,25431],"class_list":["post-351413","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-amrutanjan-health-care","tag-analyst-review","tag-healthcare-fmcg"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["351412"],"rank_math_title":["Amrutanjan Share Price Target 2027: Key Facts"],"rank_math_description":["Amrutanjan analyst review 2027: Q2 FY27 profit up 24%, sales up 15%, Comfy hygiene growth, weak H1, no broker target, 25x P\/E, share price target 2027."],"rank_math_focus_keyword":["Amrutanjan analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/amrutanjan-analyst-review-2027-q2-profit-up-24-hygiene-grows-fast-and-the-stock.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=351413"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351413\/revisions"}],"predecessor-version":[{"id":351414,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351413\/revisions\/351414"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/351412"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=351413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=351413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=351413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}